S&P 500   3,962.19 (-0.03%)
DOW   33,719.25 (-0.18%)
QQQ   284.06 (+0.07%)
AAPL   144.20 (+1.09%)
MSFT   246.83 (-0.23%)
META   116.81 (+1.28%)
GOOGL   93.47 (-0.26%)
AMZN   89.27 (-1.20%)
TSLA   179.42 (+3.45%)
NVDA   173.17 (+0.86%)
NIO   12.76 (-4.85%)
BABA   91.96 (-2.35%)
AMD   69.66 (-1.15%)
T   19.24 (+0.63%)
MU   55.41 (+0.38%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.30 (-1.59%)
DIS   94.00 (+1.57%)
AMC   5.89 (-2.97%)
PYPL   74.23 (+0.01%)
PFE   51.90 (+0.23%)
NFLX   325.69 (+4.97%)
S&P 500   3,962.19 (-0.03%)
DOW   33,719.25 (-0.18%)
QQQ   284.06 (+0.07%)
AAPL   144.20 (+1.09%)
MSFT   246.83 (-0.23%)
META   116.81 (+1.28%)
GOOGL   93.47 (-0.26%)
AMZN   89.27 (-1.20%)
TSLA   179.42 (+3.45%)
NVDA   173.17 (+0.86%)
NIO   12.76 (-4.85%)
BABA   91.96 (-2.35%)
AMD   69.66 (-1.15%)
T   19.24 (+0.63%)
MU   55.41 (+0.38%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.30 (-1.59%)
DIS   94.00 (+1.57%)
AMC   5.89 (-2.97%)
PYPL   74.23 (+0.01%)
PFE   51.90 (+0.23%)
NFLX   325.69 (+4.97%)
S&P 500   3,962.19 (-0.03%)
DOW   33,719.25 (-0.18%)
QQQ   284.06 (+0.07%)
AAPL   144.20 (+1.09%)
MSFT   246.83 (-0.23%)
META   116.81 (+1.28%)
GOOGL   93.47 (-0.26%)
AMZN   89.27 (-1.20%)
TSLA   179.42 (+3.45%)
NVDA   173.17 (+0.86%)
NIO   12.76 (-4.85%)
BABA   91.96 (-2.35%)
AMD   69.66 (-1.15%)
T   19.24 (+0.63%)
MU   55.41 (+0.38%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.30 (-1.59%)
DIS   94.00 (+1.57%)
AMC   5.89 (-2.97%)
PYPL   74.23 (+0.01%)
PFE   51.90 (+0.23%)
NFLX   325.69 (+4.97%)
S&P 500   3,962.19 (-0.03%)
DOW   33,719.25 (-0.18%)
QQQ   284.06 (+0.07%)
AAPL   144.20 (+1.09%)
MSFT   246.83 (-0.23%)
META   116.81 (+1.28%)
GOOGL   93.47 (-0.26%)
AMZN   89.27 (-1.20%)
TSLA   179.42 (+3.45%)
NVDA   173.17 (+0.86%)
NIO   12.76 (-4.85%)
BABA   91.96 (-2.35%)
AMD   69.66 (-1.15%)
T   19.24 (+0.63%)
MU   55.41 (+0.38%)
CGC   2.93 (-5.18%)
F   13.23 (+0.84%)
GE   82.30 (-1.59%)
DIS   94.00 (+1.57%)
AMC   5.89 (-2.97%)
PYPL   74.23 (+0.01%)
PFE   51.90 (+0.23%)
NFLX   325.69 (+4.97%)
NASDAQ:NDRA

ENDRA Life Sciences - NDRA Stock Forecast, Price & News

$3.55
-0.04 (-1.06%)
(As of 12/9/2022 12:27 PM ET)
Add
Compare
Today's Range
$3.28
$3.82
50-Day Range
$0.16
$0.34
52-Week Range
$0.16
$0.91
Volume
3,476 shs
Average Volume
272,803 shs
Market Capitalization
$224.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.63

ENDRA Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.3% Upside
$4.63 Price Target
Short Interest
Healthy
0.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.45mentions of ENDRA Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1,700 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

353rd out of 1,022 stocks

Electromedical Equipment Industry

8th out of 23 stocks

NDRA stock logo

About ENDRA Life Sciences (NASDAQ:NDRA) Stock

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

NDRA Stock News Headlines

ENDRA Life Sciences Earnings Preview
Xlife Sciences with pleasing progress in the first half of 2022
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Reports In-Line Q2 EPS
Endra Life Sciences Q2 2022 Earnings Preview
Preview: ENDRA Life Sciences Earnings
See More Headlines
Receive NDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

NDRA Company Calendar

Last Earnings
11/14/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NDRA
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.63
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+30.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-11,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.25 per share

Miscellaneous

Free Float
59,763,000
Market Cap
$224.25 million
Optionable
Not Optionable
Beta
0.93

Key Executives

  • Mr. Francois Michelon (Age 56)
    Chairman, Pres & CEO
    Comp: $511.64k
  • Mr. Michael  ThorntonMr. Michael Thornton (Age 54)
    Chief Technology Officer
    Comp: $358.75k
  • Mr. Renaud Bertrand Maloberti (Age 53)
    Chief Commercial Officer
    Comp: $321.53k
  • Dr. Jonathan Behr Ph.D.
    Co-Founder
  • Ms. Irina Pestrikova (Age 35)
    Sr. Director of Fin. & Sec.
  • Mr. Steve Freeman
    HR Leader













NDRA Stock - Frequently Asked Questions

Should I buy or sell ENDRA Life Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NDRA shares.
View NDRA analyst ratings
or view top-rated stocks.

What is ENDRA Life Sciences' stock price forecast for 2023?

1 analysts have issued 12 month target prices for ENDRA Life Sciences' stock. Their NDRA share price forecasts range from $4.25 to $5.00. On average, they anticipate the company's stock price to reach $4.63 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts price targets for NDRA
or view top-rated stocks among Wall Street analysts.

How have NDRA shares performed in 2022?

ENDRA Life Sciences' stock was trading at $0.6918 at the beginning of the year. Since then, NDRA shares have increased by 413.2% and is now trading at $3.55.
View the best growth stocks for 2022 here
.

When is ENDRA Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our NDRA earnings forecast
.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), Vista Gold (VGZ), electroCore (ECOR) and Genocea Biosciences (GNCA).

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

What is ENDRA Life Sciences' stock symbol?

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

Who are ENDRA Life Sciences' major shareholders?

ENDRA Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.58%) and Renaissance Technologies LLC (0.45%). Insiders that own company stock include Alexander Y Tokman, Anthony Digiandomenico, David R Wells, Francois Roger Michelon, Lou Basenese, Michael Milos Thornton and Renaud Bertrand Maloberti.
View institutional ownership trends
.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ENDRA Life Sciences' stock price today?

One share of NDRA stock can currently be purchased for approximately $3.55.

How much money does ENDRA Life Sciences make?

ENDRA Life Sciences (NASDAQ:NDRA) has a market capitalization of $224.25 million. The company earns $-11,230,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How can I contact ENDRA Life Sciences?

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The official website for the company is www.endrainc.com. The company can be reached via phone at (734) 335-0468 or via email at ndra@mzgroup.us.

This page (NASDAQ:NDRA) was last updated on 12/9/2022 by MarketBeat.com Staff